|
Mar 26
|
New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)
|
|
Mar 24
|
Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts
|
|
Mar 21
|
Johnson & Johnson is the latest pharma giant to court Trump with new investment plans
|
|
Mar 21
|
J&J boosts US operations with $55bn investment
|
|
Mar 21
|
Top Midday Stories: Boeing Wins Multibillion Dollar Contract to Build Fighter Jet; FedEx Shares Fall on Earnings Miss, Downbeat Guidance
|
|
Mar 21
|
J&J is latest company trying to get on Trump's good side with big U.S. investment
|
|
Mar 21
|
Johnson & Johnson Boosts Planned US Investment to More Than $55 Billion
|
|
Mar 21
|
Johnson & Johnson to Invest Over $55 Billion in U.S. in Next Four Years
|
|
Mar 21
|
Investing in the U.S.: Tracking Corporate Spending Pledges Under Trump
|
|
Mar 21
|
J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease
|
|
Mar 21
|
FDA Approves Johnson & Johnson's Tremfya For Crohn's Disease
|
|
Mar 21
|
Johnson & Johnson plans $55 billion in US investments over the next four years
|
|
Mar 21
|
J&J boosts US manufacturing as big pharma reshores
|
|
Mar 21
|
J&J boosts US investments by 25% over 4 years amid looming tariff threats
|
|
Mar 21
|
Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years
|
|
Mar 21
|
FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease
|
|
Mar 20
|
U.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's disease
|
|
Mar 20
|
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025
|
|
Mar 19
|
JNJ's Nipocalimab Gets FDA's Fast Track Tag for Sjogren's Disease
|
|
Mar 19
|
The Zacks Analyst Blog Highlights Visa, Johnson & Johnson, Thermo Fisher and AMREP
|